Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.